Filarete Foundation, viale Ortles 22/4, 20139 Milano, Italy.
SEMM, European School of Molecular Medicine , Campus IFOM-IEO, via Adamello 16, 20139 Milano, Italy.
Biomacromolecules. 2017 Feb 13;18(2):452-460. doi: 10.1021/acs.biomac.6b01546. Epub 2017 Jan 18.
Poly(d,l-lactic-co-glycolic acid) (PLGA) nanoparticles (NPs) are among the most studied systems for drug and gene targeting. So far, the synthesis of stable and uniform PLGA NPs has involved the use of a large excess of polyvinyl surfactants such as poly(vinyl alcohol) (PVA) and polyvinylpyrrolidone (PVP), whose removal requires multistep purification procedures of high ecological and economic impact. Hence the development of environment-friendly and cost-effective synthetic procedures for the synthesis of PLGA NPs would effectively boost their use in clinics. This work aims to address this issue by investigating more efficacious alternatives to the so far employed polyvinyl surfactants. More specifically, we developed an innovative synthetic process to achieve stable and uniformly distributed PLGA NPs that involves the use of calcium stearate (CSt), gaining benefits of its high biocompatibility and efficacy at low concentrations and avoiding consequently expensive purification steps. With the help of minimum quantities of polysorbate 60 and sorbitane monostearate, CSt-stabilized PLGA NPs with different sizes and structures were synthesized. The influence of CSt on the encapsulation efficiency of bioactive molecules has been also investigated. The effective encapsulation of both hydrophobic (curcumin) and hydrophilic (fibrinogen labeled with Alexa647) biomolecules into NPs was demonstrated by confocal microscopy, and their release quantified by spectrofluorimetric analyses. Finally, degradation and cytotoxicity studies showed that CSt stabilized NPs were stable under physiological conditions and with good biocompatibility, thus looking promising for further investigation as controlled release devices.
聚(丙交酯-乙交酯)(PLGA)纳米颗粒(NPs)是药物和基因靶向最常用的系统之一。到目前为止,稳定且均匀的 PLGA NPs 的合成涉及使用大量的聚乙烯基表面活性剂,如聚乙烯醇(PVA)和聚乙烯吡咯烷酮(PVP),其去除需要多步高生态和经济影响的纯化程序。因此,开发环境友好且具有成本效益的 PLGA NPs 合成方法将有效地促进其在临床中的应用。这项工作旨在通过研究更有效的替代目前使用的聚乙烯基表面活性剂来解决这个问题。更具体地说,我们开发了一种创新的合成工艺,以实现稳定且均匀分布的 PLGA NPs,该工艺涉及使用硬脂酸钙(CSt),从而受益于其高生物相容性和在低浓度下的功效,并避免昂贵的纯化步骤。在聚山梨酯 60 和山梨糖醇单硬脂酸酯的少量帮助下,合成了具有不同尺寸和结构的 CSt 稳定的 PLGA NPs。还研究了 CSt 对生物活性分子包封效率的影响。通过共聚焦显微镜证明了疏水分子(姜黄素)和亲水分子(标记有 Alexa647 的纤维蛋白原)有效包封到 NPs 中,并通过荧光光谱分析定量了它们的释放。最后,降解和细胞毒性研究表明,CSt 稳定的 NPs 在生理条件下稳定且具有良好的生物相容性,因此有望作为控释装置进一步研究。